Last updated: February 15, 2026
Overview
NDC 00480-8701 corresponds to NuvaRing, a vaginal contraceptive ring combining ethinyl estradiol and etonogestrel. It is used for pregnancy prevention in women of reproductive age. The product has held a significant market position since FDA approval in 2001, with consistent demand driven by its contraceptive efficacy and ease of use.
Market Size and Trends
The global contraceptive market was valued at approximately $20 billion in 2022 and projected to reach $26 billion by 2027, with a compound annual growth rate (CAGR) of 5.2%.[1] NuvaRing retains a substantial share due to its user preference, despite competition from pills, implants, IUDs, and newer hormonal offerings.
In the United States, the contraceptive market is mature, with approximately 62% of women aged 15–49 using some form of contraception, and NuvaRing's market share around 10-15% among prescription hormonal methods.[2] Sales volume stabilized post-2015, with fluctuations based on insurance coverage, provider prescribing habits, and generational shifts towards long-acting reversible contraceptives (LARCs).
Competitive Landscape
Key competitors include:
- Oral contraceptive pills (e.g., brands like Ortho Tri-Cyclen)
- IUDs (e.g., Mirena, Skyla)
- Injectable contraceptives (e.g., Depo-Provera)
- Other vaginal rings (e.g., Annovera, which offers a 13-month hormonal ring with reusability)
Market competition affects pricing, with NuvaRing priced typically between $300 and $500 per month retail in the U.S. insurance coverage often reduces patient out-of-pocket costs.
Pricing Analysis
- Current retail price: Approximately $350–$450 monthly in the U.S.
- Insurance impact: Coverage often reduces patient costs to $20–$50, depending on plans.
- Wholesale acquisition cost (WAC): Estimated at $250–$300 per device (per 28-day ring), with bulk discounts affecting actual net prices.
Price Trends & Projection
Over the past decade, prices have experienced modest declines (~3–5% annually) due to increased competition, insurance negotiations, and patent expiries of alternative products. The introduction of new formulations like Annovera (approved in 2018) and increasing adoption of LARCs are expected to exert downward pressure on NuvaRing pricing.
Projected Price Outlook (2023–2028)
- Short-term (2023–2025): Prices will likely remain stable or decline slightly, averaging a 2–3% annual decrease.
- Medium-term (2025–2028): Prices may decline further, reaching $280–$430 retail, driven by patent expiries of competing products and increased generic availability, if any.
- Influencing factors:
- Patent expiry in 2027 in the U.S. could lead to generic competition, significantly reducing prices.
- Payer negotiations and formulary positioning will influence net prices.
- Market shifts towards LARCs could reduce demand and pressure pricing.
Regulatory and Patent Environment
- NuvaRing's patent protection has been extended until 2027 via U.S. market exclusivity, delaying generic entry.[3]
- Amendments and new formulations like Annovera impact market dynamics.
- Patent expiration in 2027 will likely trigger a price decline due to the entry of generic competitors.
Market Risks & Opportunities
- Risks include increased competition from generics, adoption of LARCs, and regulatory changes.
- Opportunities involve expanding into emerging markets where contraceptive access is increasing and developing new delivery systems targeting patient preferences.
| Summary Table |
Metric |
Current |
Projection (2023–2028) |
Notes |
| Retail price |
$350–$450/month |
$280–$430/month |
Slight decline expected |
| Insurance coverage |
Major driver of patient cost |
Stable |
May influence demand slightly |
| Patent expiry |
2027 |
Competitive pressure increases |
May lower prices significantly |
| Market share |
Approx. 10–15% among hormonal contraceptives |
Decline possible with generics |
Depends on market dynamics |
Key Takeaways
- NuvaRing holds a significant share of the hormonal contraceptive market, with stable demand.
- Prices are declining modestly due to competition and market maturation.
- Patent expiration in 2027 may trigger substantial price drops with the entry of generics.
- Future growth depends on expanding into new markets and product innovation.
- Cost reductions post-patent expiry will influence both market share and profitability.
FAQs
1. When is NuvaRing’s patent set to expire?
In the United States, patent exclusivity is projected to end in 2027, opening the market for generic competitors.
2. How does insurance coverage affect NuvaRing pricing?
Insurance often covers most of the cost, reducing patient out-of-pocket expenses to $20–$50 per month, which sustains demand despite high retail prices.
3. What are the main competitors to NuvaRing?
Oral contraceptives, IUDs, injections, and newer vaginal rings like Annovera.
4. How might patent expiry impact sales?
It could lead to price reductions and increased market penetration of generics, affecting profitability.
5. What market segments are expanding for contraceptives?
Emerging markets and regions with improving healthcare access present growth opportunities, especially for affordable generic options.
Sources
[1] Grand View Research. Contraceptive Market Size, Share & Trends Analysis. 2022.
[2] Guttmacher Institute. Contraceptive Use in the United States, 2021.
[3] U.S. Patent and Trademark Office. Patent expiration records.
